ORAGENICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ORAGENICS, INC. (OGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.52 per share for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-13.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2018-08-13
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2018-06-30 was $1.52, a 57.78% decline year-over-year.
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2017-09-30 was $0.00.
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2017-06-30 was $3.60, a 520.69% increase year-over-year.
- ORAGENICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2016-09-30 was $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month |
|---|---|---|---|---|---|
| 2018-06-30 | $1.52 10-Q · filed 2018-08-13 | $1.52 10-Q · filed 2018-08-13 | |||
| 2017-09-30 | $0.00 10-Q · filed 2017-10-31 | $0.37 10-Q · filed 2017-10-31 | |||
| 2017-06-30 | $3.60 10-Q · filed 2018-08-13 | $0.36 10-Q · filed 2017-08-14 | $3.60 10-Q · filed 2018-08-13 | $0.36 10-Q · filed 2017-08-14 | |
| 2016-09-30 | $0.00 10-Q · filed 2017-10-31 | $0.72 10-Q · filed 2017-10-31 | |||
| 2016-06-30 | $0.58 10-Q · filed 2017-08-14 | $0.72 10-Q · filed 2017-08-14 | |||
| 2016-03-31 | $0.82 10-Q · filed 2017-05-15 | ||||
| 2015-09-30 | $0.00 10-Q · filed 2016-11-14 | $1.29 10-Q · filed 2016-11-14 | |||
| 2015-06-30 | $0.77 10-Q · filed 2016-08-15 | $1.29 10-Q · filed 2016-08-15 | |||
| 2015-03-31 | $1.30 10-Q · filed 2016-05-16 | ||||
| 2014-09-30 | $0.00 10-Q · filed 2015-11-06 | $2.81 10-Q · filed 2015-11-06 | |||
| 2014-06-30 | $2.81 10-Q · filed 2015-08-07 | $2.81 10-Q · filed 2015-08-07 | |||
| 2013-09-30 | $0.00 10-Q · filed 2014-11-03 | $3.41 10-Q · filed 2014-11-03 | |||
| 2013-06-30 | $3.32 10-Q · filed 2014-08-07 | $3.41 10-Q · filed 2014-08-07 | |||
| 2013-03-31 | $3.52 10-Q · filed 2014-05-09 | ||||
| 2012-09-30 | $0.00 10-Q · filed 2013-10-25 | $1.03 10-Q · filed 2013-10-25 | |||
| 2012-06-30 | $0.00 10-Q · filed 2013-08-12 | $1.03 10-Q · filed 2013-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |